Patient characteristic | All patients (N = 288) | Discovery cohort (N = 201) | Internal validation cohort (N = 87) |
---|---|---|---|
Female sex, n (%) | 171/288 (59.4) | 116/201 (57.7) | 55/87 (63.2) |
Age, years, median [IQR] | |||
Duration of illness prior to admission, days, median [IQR]a | |||
History of fever, n (%) | 288/288 (100.0) | 201/201 (100.0) | 87/87 (100.0) |
Night sweats | 225/288 (78.1) | 161/201 (80.1) | 64/87 (73.6) |
Headache | 227/288 (78.8) | 158/201 (78.6) | 69/87 (79.3) |
Cough | 178/288 (61.8) | 125/201 (62.2) | 53/87 (60.9) |
Diarrhea | 100/288 (34.7) | 70/201 (34.8) | 30/87 (34.5) |
Shortness of breath | 66/288 (22.9) | 47/201 (23.4) | 19/87 (21.8) |
Dysuria | 39/288 (13.5) | 31/201 (15.4) | 8/87 (9.2) |
Received antibiotic or antimalarial agent prior to admission, n (%) | 102/288 (35.4) | 70/201 (34.8) | 32/87 (36.8) |
Temperature ≥ 38 °C, n (%) | 104/288 (36.1) | 76/201 (37.8) | 28/87 (32.2) |
Temperature < 36 °C, n (%) | 84/288 (29.2) | 58/201 (28.9) | 26/87 (29.9) |
Heart rate, beats/min, median [IQR] | 98 [87,109] | 98 [86,108] | 98 [90,111] |
Respiratory rate, beats/min, median [IQR] | |||
Systolic blood pressure, mmHg, median [IQR] | 103 [91,117] | 104 [91,118] | 100 [92,113] |
Oxygen saturation, %, median [IQR] | 97 [95,98] | 97 [96,98] | 97 [95,98] |
Encephalopathy, n (%)b | 57/288 (19.8) | 40/201 (19.9) | 17/87 (19.5) |
qSOFA score ≥ 2, n (%)c | 129/288 (44.8) | 88/201 (43.8) | 41/87 (47.1) |
qSOFA score ≥ 1, n (%)c | 253/288 (87.8) | 174/201 (86.6) | 79/87 (90.8) |
Modified SIRS score ≥ 2, n (%)d | 247/288 (85.8) | 173/201 (86.1) | 74/87 (85.1) |
MEWS, median [IQR] | |||
UVA score, median [IQ R] | |||
Shock, n (%)e | 41/288 (14.2) | 28/201 (13.9) | 13/87 (14.9) |
Acute respiratory failure, n (%)f | 61/288 (21.2) | 39/201 (19.4) | 22/87 (25.3) |
Severe anemia, n (%)g | 56/288 (19.4) | 39/201 (19.4) | 17/87 (19.5) |
HIV-infected, n (%) | 154/286 (53.8) | 106/199 (53.2) | 48/87 (55.2) |
WHO clinical stage 3 or 4, n (%) | 125/154 (81.2) | 91/106 (85.8) | 34/48 (71.0) |
Newly diagnosed HIV-infection, n (%) | 20/154 (13.0) | 12/106 (11.3) | 8/48 (16.7) |
On ART prior to admission, n (%)h | 91/134 (67.9) | 63/94 (67.0) | 28/40 (70.0) |
On TMP-SMX prior to admission, n (%)h | 94/134 (70.1) | 65/94 (69.1) | 29/40 (72.5) |
Malaria RDT positive, n (%) | 59/283 (20.8) | 38/197 (19.3) | 21/86 (24.4) |
Microbiological TB positive, n (%)i | 51/288 (17.7) | 35/201 (17.4) | 16/87 (18.4) |
Urine TB-LAM positive | 40/122 (32.8) | 27/83 (32.5) | 13/39 (33.3) |
Influenza PCR positive, n (%) | 17/262 (6.5) | 14/184 (7.6) | 3/78 (3.8) |
Death in-hospital or transfer, n (%) | 40/288 (13.9) | 28/201 (13.9) | 12/87 (13.8) |
Duration of hospitalization, days, median [IQR]j | |||
KPS ≤ 70 at alive discharge, n (%) | 20/246 (8.1) | 12/173 (6.9) | 8/73 (11.0) |
Death at 30-days post-discharge, n (%) | 62/260 (23.8) | 44/179 (24.6) | 18/81 (22.2) |